The statement you provided describes the results of a vaccination approach in patients with HER-2-overexpressing gastric cancer (GC).
Let's break down what this means:HER-Vaxx-based vaccination: This refers to a vaccination strategy that is designed to target HER-2/neu, a protein that is overexpressed in some cancer cells, including gastric cancer.
The vaccination likely involves administering a vaccine (HER-Vaxx) to the patients.HER-2-overexpressing GC: This specifies the type of cancer being targeted. It's gastric cancer (GC) in which the HER-2/neu protein is overexpressed. Overexpression of HER-2/neu is associated with more aggressive cancer and is a therapeutic target.Induced anti-HER-2-IgG and IgG1 subclass antibody responses (p<0.001):
This indicates that the vaccination led to the production of antibodies against the HER-2 protein. IgG antibodies are a class of antibodies in the immune system, and IgG1 is a subclass of IgG. The "p<0.001" suggests that the production of these antibodies was statistically significant, indicating a strong immune response.Dose-dependent functionality in binding to Her-2/neu-expressing cells:
This means that the antibodies produced by the vaccination have the ability to bind effectively to cancer cells that overexpress the HER-2/neu protein. Moreover, the effectiveness of this binding increases with the vaccine dose, showing a dose-dependent response.Intracellular phosphorylation inhibition of the receptor and the signaling pathway kinases Akt and MAPK:
This indicates that the antibodies generated by the vaccination are not only binding to the HER-2/neu protein on the surface of cancer cells but are also capable of inhibiting the phosphorylation of the receptor and the downstream signaling pathway kinases Akt and MAPK.
This is a critical result because it suggests that the vaccination is interfering with the cancer cell's growth and signaling processes.
In summary, the HER-Vaxx-based vaccination in patients with HER-2-overexpressing gastric cancer appears to be effective. It induces a strong immune response, resulting in the production of antibodies that can bind to cancer cells and, importantly, inhibit the intracellular signaling pathways related to cell growth. This is a promising development in the treatment of HER-2/neu-positive gastric cancer
- Forums
- ASX - By Stock
- IMU
- Ann: Imugene B Cell & OV Platforms Featured at ESMO Congress
Ann: Imugene B Cell & OV Platforms Featured at ESMO Congress, page-122
-
-
- There are more pages in this discussion • 67 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.3¢ |
Change
-0.001(1.85%) |
Mkt cap ! $389.5M |
Open | High | Low | Value | Volume |
5.5¢ | 5.6¢ | 5.3¢ | $615.0K | 11.39M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
25 | 2977440 | 5.3¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.4¢ | 283236 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
25 | 2977440 | 0.053 |
25 | 3109336 | 0.052 |
24 | 2300422 | 0.051 |
66 | 4218756 | 0.050 |
23 | 3155527 | 0.049 |
Price($) | Vol. | No. |
---|---|---|
0.054 | 283236 | 4 |
0.055 | 1134647 | 7 |
0.056 | 1642592 | 7 |
0.057 | 1624353 | 11 |
0.058 | 230000 | 3 |
Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
MTL
MANTLE MINERALS LIMITED
Nick Poll, Executive Director
Nick Poll
Executive Director
SPONSORED BY The Market Online